All In Biotech

Drug Trial Radar · NCT04784910

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 423 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

423

Actual

Start

May 21, 2021

Primary completion

Nov 27, 2023

Study completion Dec 11, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.

Conditions

  • Peptic Ulcer

Interventions

  • DWP14012 20mgDrug

    DWP14012 20mg, tablet, orally, once daily for up to 24 weeks

  • Lansoprazole 15 mgDrug

    Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks

  • DWP14012 20mg placeboDrug

    DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks

  • Lansoprazole 15 mg placeboDrug

    Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigatorTime frame: at 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.